ESMO 2022 | Improving the diagnosis of bladder cancer in the BladderPath study

The staging and grading of bladder cancer has not changed in over a century, with endoscopic resection determining if the cancer is muscle invasive or non-muscle invasive. Nicholas James, MBBS, PhD, FRCP, FRCR, The Royal Marsden NHS Foundation Trust, London, UK, describes the rationale behind the BladderPath study (ISRCTN35296862), which aims to replace the current, invasive techniques with scans and biopsies to diagnose bladder cancer. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.